Sexual dysfunction in a cohort of patients with moderate-to-severe atopic dermatitis. Influence of dupilumab treatment.
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
revised:
05
08
2021
received:
17
05
2021
accepted:
20
09
2021
pubmed:
12
10
2021
medline:
22
4
2022
entrez:
11
10
2021
Statut:
ppublish
Résumé
Atopic dermatitis is a systemic and immune-mediated dermatological disease that comprises a wide group of physiological and psychological comorbidities. Within the latter, the evaluation of anxiety and depression has been the subject of numerous studies, but sexual dysfunction (SD) is a fact that is rarely addressed in the literature. The objective of the present study is to assess the prevalence of SD in a cohort of patients with moderate-to-severe atopic dermatitis (AD) and to establish the possible impact of dupilumab therapy on it. A cross-sectional study was performed. Recruited patients had been diagnosed with moderate-to-severe AD at the Dermatology Unit of the Hospital Universitario San Cecilio, Granada, Spain, from July 1, 2019, through June 30, 2020. They were followed up for a 6-month period during which the impact of dupilumab treatment was measured. The main variable under study, sexual dysfunction, was evaluated differently according to gender. Regarding the male patients, the International Index Erectile Function (IIEF-5) was applied, whereas for female patients, the questionnaire "Female Sexual Function Index" was used. Our study included 31 patients, 18 men and 13 women. Men's mean age was 35 +/- 14.55 years, while that of women was 33 +/- 10.46 years. Seventy-nine percent of patients in our series (n = 22) had SD compared to 29% (n = 9) who did not. A total of 66.9% of males and 76.9% (n = 10) of females sampled, suffered from SD. Six months after initiation of treatment, none of the patient had stopped it due to efficacy or safety issues. All severity indices (SCORAD, EASI, VAS pruritus, and DLQI) had significantly improved by more than 50% from baseline. The improvement in the sexual dysfunction index had improved by four points, both in the male and female patients. Many large population studies on SD in patients with moderate-to-severe atopic AD only focus on male gender and clinical diagnoses, rather than specific and validated questionnaires. Dupilumab treatment in patients with moderate-to-severe AD has shown a positive impact on the levels of SD in both male and female populations. Further studies focused on populations with mild atopic AD and with larger sample sizes are required to corroborate these preliminary results.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
dupilumab
420K487FSG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
607-610Informations de copyright
© 2021 the International Society of Dermatology.
Références
Koszorú K, Borza J, Gulácsi L, Sárdy M. Quality of life in patients with atopic dermatitis. Cutis 2019; 104: 174-177.
Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol 2018; 121: 340-347.
Rønnstad ATM, Halling-Overgaard AS, Hamann CR, et al. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis [Internet]. J Am Acad Dermatol 2018; 79: 448-456.e30.
Wespes E, Amar E, Eardley I, et al. Guía clínica sobre la disfunción sexual masculina : disfunción eréctil y eyaculación precoz. Eur Assoc Urol 2010; 2010: 1-58.
Blümel MJE, Binfa EL, Cataldo AP, Carrasco VA, Izaguirre LH, Sarrá CS. Índice de función sexual femenina: un test para evaluar la sexualidad de la mujer. Rev Chil Obstet Ginecol 2004; 69: 118-125.
Clayton AH, Valladares Juarez EM. Female sexual dysfunction. Med Clin North Am 2019; 103: 681-698.
Rosen R, Cappelleri J, Smith M, Lipsky J, Peña B. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319-326.
Ermertcan AT. Sexual dysfunction in dermatological diseases. J Eur Acad Dermatology Venereol 2009; 23: 999-1007.
Latif EZ, Diamond MP. Arriving at the diagnosis of female sexual dysfunction. Fertil Steril 2013; 100: 898-904.
Sampogna F, Abeni D, Gieler U, et al. Impairment of sexual life in 3,485 dermatological outpatients from a multicentre study in 13 European countries. Acta Derm Venereol 2017; 97: 478-482.
Chung SD, Keller JJ, Lin HC. Association of erectile dysfunction with atopic dermatitis: a population-based case-control study. J Sex Med 2012; 9: 679-685.
Ludwig CM, Fernandez JM, Hsiao JL, Shi VY. The interplay of atopic dermatitis and sexual health. Dermatitis 2020; 31: 303-308.
Misery L, Finlay AY, Martin N, et al. Atopic dermatitis: impact on the quality of life of patients and their partners. Dermatology 2007; 215: 123-129.
Misery L, Seneschal J, Reguiai Z, et al. The impact of atopic dermatitis on sexual health. J Eur Acad Dermatology Venereol 2019; 33: 428-432.
Long CC, Funell CM, Collard R, et al. What do members of the National Eczema Society really want? Clin Exp Dermatol 1993; 18: 516-522.
Ruiz-Villaverde R, Armario-Hita JC, Dominguez-Cruz J, et al. The safety of dupilumab in clinical practice: 52 weeks of experience at 5 referral hospitals in Andalusia. Actas Dermosifiliogr 2020; 111: 699-700.
Armario-Hita JC, Pereyra-Rodriguez J, Silvestre JF, et al. Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series. Br J Dermatol 2019; 181: 1072-1074.